Auxilium Pharmaceuticals (NASDAQ: AUXL) is one of 48 public companies in the “Biopharmaceuticals” industry, but how does it contrast to its peers? We will compare Auxilium Pharmaceuticals to similar businesses based on the strength of its valuation, analyst recommendations, earnings, dividends, risk, profitability and institutional ownership.
Risk & Volatility
Auxilium Pharmaceuticals has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, Auxilium Pharmaceuticals’ peers have a beta of 1.03, suggesting that their average share price is 3% more volatile than the S&P 500.
43.2% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 15.4% of shares of all “Biopharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Auxilium Pharmaceuticals and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Auxilium Pharmaceuticals Competitors||$564.12 million||$96.17 million||40.99|
Auxilium Pharmaceuticals’ peers have higher revenue and earnings than Auxilium Pharmaceuticals. Auxilium Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Auxilium Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Auxilium Pharmaceuticals Competitors||-13,602.79%||-100.87%||-25.29%|
This is a summary of recent ratings for Auxilium Pharmaceuticals and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Auxilium Pharmaceuticals Competitors||137||800||1748||59||2.63|
As a group, “Biopharmaceuticals” companies have a potential upside of 13.74%. Given Auxilium Pharmaceuticals’ peers higher possible upside, analysts clearly believe Auxilium Pharmaceuticals has less favorable growth aspects than its peers.
Auxilium Pharmaceuticals peers beat Auxilium Pharmaceuticals on 5 of the 8 factors compared.
Auxilium Pharmaceuticals Company Profile
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company that focuses on developing and marketing products to predominantly specialist audiences. Its core therapeutic focus continues to be in the area of urology, with an anchor position in men’s healthcare. The company’s products include Testim (testosterone gel) and testosterone gel are indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; TESTOPEL offers men an option that provides a long-acting androgenic effect; Striant (testosterone buccal system) CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction; among others.
What are top analysts saying about Auxilium Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Auxilium Pharmaceuticals Inc and related companies.